Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Kidney Graft Function Under the Immunosuppression Strategies With Low Dose of Neoral(R)(Cyclosporine) and Standard Dose of Myfortic(R)(Enteric-Coated Mycophenolate Sodium) vs. With Conventional Dose of Neoral(R)(Cyclosporine) and Reduced Dose of Myfortic(R)(Enteric-Coated Mycophenolate Sodium) in De Novo Renal Transplant Recipients

Trial Profile

Kidney Graft Function Under the Immunosuppression Strategies With Low Dose of Neoral(R)(Cyclosporine) and Standard Dose of Myfortic(R)(Enteric-Coated Mycophenolate Sodium) vs. With Conventional Dose of Neoral(R)(Cyclosporine) and Reduced Dose of Myfortic(R)(Enteric-Coated Mycophenolate Sodium) in De Novo Renal Transplant Recipients

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2014

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms MyLowCsA
  • Most Recent Events

    • 05 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top